CRISPR unicorn Mammoth backs off diagnostics research, laying off 35 on testing team to focus on therapeutics
Mammoth Biosciences is taking a big step away from its original ambition of upending the diagnostics business with CRISPR, and has laid off the bulk of its employees working on testing.
The Brisbane, CA-based startup laid off 35 people, or less than 20% of its workforce, in March, Mammoth CEO Trevor Martin confirmed to Endpoints News. The cuts have not been previously reported, and primarily affected people working on the diagnostics team.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.